IL17A and rheumatoid arthritis: Bimekizumab, a dual inhibitor of IL-17A/IL-17F approved for psoriasis, was efficacious when combined with certolizumab in RA patients who initially (8 wk) displayed inadequate response to certolizumab alone in a phase 2a trial (NCT02430909) and reduced disease activity levels on-par with responders on certolizumab alone by week 44 (Glatt et al., 2019).